BioLife Solutions, Inc. (NASDAQ:BLFS) Short Interest Update

BioLife Solutions, Inc. (NASDAQ:BLFS) was the recipient of a significant growth in short interest in the month of November. As of November 30th, there was short interest totalling 3,240,000 shares, a growth of 20.9% from the November 15th total of 2,680,000 shares. Based on an average trading volume of 384,100 shares, the short-interest ratio is currently 8.4 days.

BioLife Solutions Trading Down 0.1 %

Shares of BLFS stock traded down $0.02 on Friday, hitting $26.70. 365,400 shares of the company’s stock traded hands, compared to its average volume of 383,235. The stock has a market capitalization of $1.24 billion, a price-to-earnings ratio of -25.19 and a beta of 1.91. The company’s fifty day simple moving average is $24.62 and its 200 day simple moving average is $23.55. BioLife Solutions has a one year low of $13.99 and a one year high of $28.88. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78.

Insider Transactions at BioLife Solutions

In other BioLife Solutions news, CRO Garrie Richardson sold 3,070 shares of the stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $25.12, for a total value of $77,118.40. Following the sale, the executive now directly owns 114,773 shares in the company, valued at $2,883,097.76. This represents a 2.61 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Aby J. Mathew sold 17,604 shares of the business’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $20.05, for a total transaction of $352,960.20. Following the transaction, the executive vice president now owns 284,442 shares of the company’s stock, valued at $5,703,062.10. This trade represents a 5.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 71,313 shares of company stock valued at $1,572,899 over the last three months. Company insiders own 2.20% of the company’s stock.

Institutional Investors Weigh In On BioLife Solutions

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Fred Alger Management LLC lifted its position in BioLife Solutions by 6.0% in the second quarter. Fred Alger Management LLC now owns 1,579,138 shares of the medical equipment provider’s stock valued at $33,841,000 after purchasing an additional 88,840 shares during the last quarter. State Street Corp increased its stake in shares of BioLife Solutions by 7.3% in the third quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock worth $35,364,000 after buying an additional 95,788 shares during the period. Geode Capital Management LLC raised its holdings in BioLife Solutions by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock valued at $21,107,000 after buying an additional 18,473 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in BioLife Solutions by 9.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 794,971 shares of the medical equipment provider’s stock worth $17,034,000 after acquiring an additional 66,422 shares during the last quarter. Finally, Rockefeller Capital Management L.P. increased its position in shares of BioLife Solutions by 81.3% in the third quarter. Rockefeller Capital Management L.P. now owns 585,497 shares of the medical equipment provider’s stock valued at $14,661,000 after acquiring an additional 262,504 shares during the period. Institutional investors own 93.24% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on BLFS. KeyCorp raised their price target on BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a report on Friday. Craig Hallum raised their target price on shares of BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. HC Wainwright cut their price target on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a research note on Monday, November 18th. Finally, TD Cowen increased their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. According to MarketBeat, BioLife Solutions has a consensus rating of “Moderate Buy” and a consensus price target of $28.29.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.